|
Jun 14
|
Johnson & Johnson (NYSE:JNJ) Unveils Promising CAR T-Cell Therapy for B-Cell Lymphoma
|
|
Jun 14
|
UBS Backs Johnson & Johnson as a Defensive Play in Uncertain Times
|
|
Jun 14
|
Healthcare Sector Taps AI Boom via Intuitive Surgical Stock (ISRG)
|
|
Jun 13
|
Sector Update: Health Care Stocks Softer Friday Afternoon
|
|
Jun 13
|
JPMorgan biotech/pharma analysts hold analyst/industry conference call
|
|
Jun 13
|
Johnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma
|
|
Jun 13
|
BSX Q1 Endoscopy Sales Rise 6%: What's Behind the Growth?
|
|
Jun 12
|
New results for Johnson & Johnson's bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia
|
|
Jun 12
|
J&J’s Tremfya reduces active psoriatic arthritis symptoms in Phase IIIb trial
|
|
Jun 11
|
Judge Orders J&J Subsidiary to Pay $442 Million in Antitrust Lawsuit
|
|
Jun 11
|
Daniel Pinto Joins Johnson & Johnson (NYSE:JNJ) Board Bringing Extensive Financial Expertise
|
|
Jun 11
|
Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel
|
|
Jun 11
|
Why Johnson & Johnson (JNJ) is a Top Momentum Stock for the Long-Term
|
|
Jun 11
|
JNJ vs. MRK: Which Healthcare Titan Offers Better Growth Prospects?
|
|
Jun 11
|
The Zacks Analyst Blog Highlights Johnson & Johnson, T-Mobile, The Boeing and Franklin Financial Services
|
|
Jun 11
|
New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis
|
|
Jun 11
|
Why defensive stocks could be your best bet in a wild market
|
|
Jun 11
|
Johnson & Johnson MedTech introduces surgical stapler for tissue complexity
|
|
Jun 10
|
Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors
|
|
Jun 10
|
Top Analyst Reports for Johnson & Johnson, T-Mobile US & Boeing
|